Occurrence of peptic ulcer disease in connective tissue disease patients associated with xerostomia

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 217-224

  Luo, J C ^a   Lin, H Y ^a   Chang, F Y ^a   Lu, R H ^a   Lu, C L ^a   Chen, C Y ^a   Lee, S D ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADULT; AGE; AGED; AGING; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ENDOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; SALIVARY GLAND FUNCTION; SALIVATION; XEROSTOMIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; DYSPEPSIA; EPIDERMAL GROWTH FACTOR; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; REGRESSION ANALYSIS; RISK FACTORS; XEROSTOMIA;

EID: 0037312634     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01418.x     Document Type: Article

References (31)

1. Kongara KR, Softer EE. Saliva and esophageal protection. Am J Gastroenterol 1999; 94: 1446-52.
2. Uribe JM, Barrett KE, Nonmitogenic actions of growth factors: an integrated view of their role in intestinal physiology and pathophysiology. Gastroenterology 1997; 112: 255-68.
3. Tarnawski A, Jones MK. The role of epidermal growth factor and its receptor in mucosal protection, adaptation to injury, and ulcer healing: involvement of EGF-R signal transduction pathway. J Clin Gastroenterol 1998; 27(Suppl.): 12-20.
4. Tarnawski A, Cellular mechanism of gastric ulcer healing. In: Domschke W, Konturek SJ, eds. The Stomach. Berlin: Springer-Verlag, 1993: 177-92.
5. Konturek SJ, Dembinski A, Warzecha Z, et al. Role of epidermal growth factor in healing of chronic gastroduodenal ulcers in rats. Gastroenterology 1988; 94: 1300-7.
6. Koffman CG, Elder JB, Ganguli PC, et al. Effect of urogastrone on gastric secretion and serum gastrin concentration in patients with duodenal ulceration. Gut 1982; 23: 951-6.
7. Marrota F, Chui DH, Zhong GG, et al. Effect of graded intravenous doses of urogastrone on duodenal bicarbonate secretion in conscious rats: evidence of a dose-response pattern. Digestion 1990; 47: 88-94.
8. Sumi S, Inoue K, Hosotani R, et al. Effect of human epidermal growth factor on splanchnic circulation in dog. Life Sci 1990; 47: 1115-9.
9. Hase S, Nakazawa S, Tsukamoto Y, et al. Effects of prednisolone and human epidermal growth factors on angiogenesis in granulation tissue of gastric ulcer induced by acetic acid. Digestion 1989; 42: 135-42.
10. Konturek JW, Bielanski W, Konturek SJ, et al. Distribution and release of epidermal growth factor in man. Gut 1989; 30: 1194-200.
11. Konturek SJ, Bielanski W, Konturek JW, et al. Release and action of epidermal growth factor on gastric secretion in humans. Scand J Gastroenterol 1989; 24: 485-92.
12. Olsen PS, Poulsen SS, Kirkegaard P, et al. Role of submandibular saliva and epidermal growth factor in gastric cytoprotection. Gastroenterology 1984; 87: 103-8.
13. Uhlig T, Kvien TK, Jensen JL, et al. Sicca symptoms, saliva, and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 415-22.
14. Fujimoto M, Shimozuma M, Yazawa N, et al. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis 1997; 56: 667-70.
15. Nossent JC, Swaak AJ. Systemic lupus erythematosus VII: frequency and impact of secondary Sjögren's syndrome. Lupus 1998; 7: 231-4.
16. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Results of a prospective concerted action supported by the European Community. Preliminary Criteria for the Classification of Sjögren's Syndrome. Arthritis Rheum 1993; 36: 340-7.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 1988; 31: 315-24.
18. Tan EM, Cohen AS, Fries JF, et al. The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus, Arthritis Rheum 1982; 25: 1271-7.
19. Hochberg MC. Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum 1997; 40: 1725.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary Criteria for the Classification of Systemic Sclerosis. Arthritis Rheum 1980; 23: 581-90.
21. Luo JC, Chang FY, Lin HY, et al. The potential risk factors leading to peptic ulcer formation in autoimmune disease patients receiving corticosteroid treatment. Aliment Pharmacol Ther 2002; 16: 1241-8.
22. Korsten MA, Rosman AS, Fishbein S, et al. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 1991; 90: 701-6.
23. Workshop on Diagnostic Criteria for Sjögren's Syndrome. I. Questionnaires for dry eye and dry mouth. II. Manual of methods and procedures. Clin Exp Rheumato 1989; 7: 212-9.
24. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-34.
25. Rourk RM, Namiot Z, Sarosiek J, et al. Impairment of salivary growth factor secretory response to esophageal mechanical and chemical stimulation in patients with reflux esophagitis. Am J Guastroenterol 1994; 89: 237-44.
26. Andonopoulos AP, Drosos AA, Skopouli FN, et al. Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol 1987; 14: 1098-103.
27. Farah D, Sturrock RD, Russell RI. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 478-10.
28. Roth SH, Bennett RE, Mitchell CS. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation. Arch Intern Med 1987; 147: 1798-801.
29. Soll AH. Peptic ulcer and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds, Gastrointestinal and Liver Disease, 6th edn. Philadelphia: W. B. Saunders, 1998; 620-32.
30. Maccini DM, Veit BC. Salivary epidermal growth factor in patients with and without acid peptic disease. Am J Gastroenterol 1990; 85: 1102-4.
31. Ma L, Wang WP, Chow JYC, et al. Reduction of EGF is associated with the delay of ulcer healing by cigarette smoking. Am J Physiol 2000; 278: G10-7.